Vaxcyte Balance Sheet
NASDAQ: PCVXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Vaxcyte financial position
At the end of fiscal 2025, Vaxcyte reported total assets of $3.00 billion, down 14.5% from a year earlier against total liabilities of $317.2 million. Shareholders' equity stood at $2.69 billion, or 89.4% of assets. The company held $174.0 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 7.91, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Vaxcyte balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 173.96M | 387.88M | 397.45M | 834.66M | 68.98M | 386.20M | 58.98M | 66.09M |
| Short-Term Investments | 1.39B | 1.36B | 682.78M | 96.72M | 176.99M | — | — | — |
| Total Current Assets | 1.63B | 1.79B | 1.10B | 942.55M | 256.35M | 389.00M | 61.72M | — |
| Property, Plant & Equipment | 257.37M | 198.04M | 79.63M | 10.36M | 7.95M | 3.27M | 3.39M | — |
| Long-Term Investments | 881.66M | 1.39B | 162.68M | 26.55M | 27.12M | — | — | — |
| Total Assets | 3.00B | 3.51B | 1.41B | 1.01B | 324.34M | 392.83M | 65.70M | — |
| Accounts Payable | 70.90M | 48.45M | 14.59M | 9.79M | 6.76M | 29.79M | 3.38M | — |
| Total Current Liabilities | 205.75M | 140.18M | 145.34M | 40.52M | 28.72M | 46.86M | 11.05M | — |
| Total Liabilities | 317.21M | 205.50M | 167.45M | 52.56M | 40.32M | 46.98M | 11.76M | — |
| Shareholders' Equity | 2.69B | 3.31B | 1.24B | 953.61M | 284.02M | 345.84M | -106.37M | -57.73M |
| Retained Earnings | -2.15B | -1.39B | -924.39M | -522.13M | -298.64M | -198.56M | -109.35M | — |
| Net Cash (Debt) | 1.56B | 1.75B | 1.08B | 931.38M | 245.97M | 386.20M | 58.98M | 66.09M |
| Shares Outstanding | 131.06M | 124.89M | 95.36M | 79.47M | 53.03M | 51.07M | 4.06M | — |
This table shows 8 annual periods of Vaxcyte's balance sheet, from FY 2025 back to FY 2018, across 13 line items including cash & equivalents, short-term investments, total current assets. Values in USD; B = billions, M = millions. Fiscal periods follow PCVX's reporting calendar. What is a balance sheet?